Exelixis Inc

Exelixis Inc. an oncology-focused biotechnology company focuses on the discovery development and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib an inhibitor of multiple tyrosine kinases including MET AXL RET and VEGF receptors. The company also offers COTELLIC an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib an oral tyrosine kinase inhibitor that targets VEGF receptors MET AXL MER and other kinases implicated in growth and spread of cancer; XB002 an antibody-drug conjugate composed of human monoclonal antibody against tissue factor (TF) for the treatment of advanced solid tumors; XL102 an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience Inc.; R.P. Scherer Technologies LLC; Catalent Pharma Solutions Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics Inc.; Invenra Inc.; StemSynergy Therapeutics Inc.; Genentech Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company Limited as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals Inc. and changed its name to Exelixis Inc. in February 2000. Exelixis Inc. was incorporated in 1994 and is headquartered in Alameda California.